---
title: "Varegacestat (AL102) in Desmoid tumors: Diagnosis"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Diagnosis. Topics: Histopathologic confirmation by core needle biopsy, Expert soft tissue pathology review, CTNNB1 mutational analysis: guideline recommendation, CTNNB1 testing and screening for familial adenomatous polyposis in 226 patients, and 11 further topics. 15 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/diagnosis"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Histopathologic confirmation by core needle biopsy

> “The histopathologic confirmation of DF is mandatory before initiating treatment.”
> “A diagnosis of DF can be readily established on core biopsies using 14G or 16G needles, while neither incisional nor excisional biopsy is recommended as the initial diagnostic modality.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “It has to be taken into account that a potential post-biopsy increase in size or pain may be due to bleeding from the biopsy rather than true tumor growth.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-2"></a>

### Expert soft tissue pathology review

> “Diagnosis of DT should be confirmed by an expert soft tissue pathologist.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “Second opinion by an expert pathologist as well as clinical management by an expert team is highly recommended”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.1.5-3"></a>

### CTNNB1 mutational analysis: guideline recommendation

> “Vice versa, CTNNB1 wild-type status in DT, especially in an intra-abdominal tumour, should raise suspicion for FAP, with more extensive diagnostic clinical work-up (e.g. colonoscopy or germline testing).”
> “Therefore, our group gives a strong recommendation to perform a mutational analysis in DT biopsy specimens to confirm diagnosis and guide the work-up when appropriate.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-4"></a>

### CTNNB1 testing and screening for familial adenomatous polyposis in 226 patients

> “226 patients were identified and 67% (n = 152) were female.”
> “Colonoscopy was requested in 65 patients (28.8% of all cases) and was completed in forty-six (20.4%). Molecular testing of CTNNB1 testing was requested in 35 cases (15.5%). APC germline test was requested in 12 cases. Four patients in our cohort had an FAP-associated DF.”
> “CTNNB1 molecular testing should be performed in all cases of newly diagnosed DF. Negative CTNNB1 results, alongside clinical assessment, should prompt APC testing and/or colonoscopy.”

Source: [Cojocaru et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/33547536/)

<a id="topic-2.2.1.5-5"></a>

### Referral for colonoscopy by tumor location and age

> “In conclusion, patients with desmoid-type fibromatoses are at risk of underlying FAP. Especially cases with desmoid localization intra-abdominal or in the abdominal wall, and all patients younger than 60 years, have a substantial increased risk and should be referred for colonoscopy.”

Source: [Nieuwenhuis et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/20830713/)

<a id="topic-2.2.1.5-6"></a>

### CTNNB1 sequencing in β-catenin-negative desmoid fibromatosis

> “A single-center, large retrospective analysis of 780 patients with DF was performed.”
> “77.3% of DF cases exhibited nuclear β-catenin positivity.”
> “Molecular analysis revealed that 74.1% of β-catenin negative cases harbored CTNNB1 mutations, primarily at codon 41 (p.T41A).”
> “Notably, β-catenin IHC showed higher positivity in resected specimens (79.7%) compared to biopsies (62.0%), whereas CTNNB1 mutational detection was higher in biopsies (93.5%) than resections (76.8%).”

Source: [Wang et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41586907/)

<a id="topic-2.2.1.5-7"></a>

### CTNNB1 testing documented at a U.S. academic center

> “Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.”
> “A much smaller proportion of patients had documentation of CTNNB1 testing ( n = 10, 6.7%), including seven with CTNNB1 mutation (4.7%) and three who were demonstrated to have the wild-type, nonmutated variant, which results in production of normal β-catenin (2%).”
> “Diagnostic methods, such as CTNNB1 testing, may also shorten the diagnostic journey.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.5-8"></a>

### Imaging: magnetic resonance imaging for diagnosis, local staging, and follow-up

> “MRI is the mainstay of imaging in DF and can be used for diagnosis, local staging and follow-up”
> “The lack of radiation exposure makes targeted MRI ideal for follow-up.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

> “Histopathological diagnosis is mandatory, and evaluation is guided with imaging studies ranging from ultrasound, computed tomography or magnetic resonance.”
> “Ultrasound (US) serves as the initial evaluation especially for tumors in the extremities or abdominal wall.”
> “Its appearance depends on the cellular composition where more fibrotic areas, with a greater amount of collagen, show a low signal intensity in T2 with moderate contrast enhancement.”

Source: [Garcia-Ortega et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7408653/)

> “Desmoid tumors are generally routine to diagnose and are usually first noted upon physical examination or by using various imaging techniques, such as ultrasound, computed tomography, or CT, or magnetic resonance imaging, or MRI.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.5-9"></a>

### Imaging schedule during active surveillance

> “Active surveillance means that patients need to be continuously monitored with a first MRI (or alternatively CT if MRI is not possible) within 1-2 months, then in 3-6 months intervals.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.1.5-10"></a>

### Response assessment: RECIST and magnetic resonance imaging signal

> “Assessment of treatment effects in DT remains an unresolved issue and no standard validated response criteria are available as of today.”
> “RECIST does not robustly identify all clinically relevant responses, though the majority of prospective trials report efficacy using RECIST.”
> “Contrast-enhanced MRI or alternatively CT are the preferred modalities for monitoring DT.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

> “MRI surveillance has been used to assess response to treatment with a decrease in T2W signal and lesion size”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.1.5-11"></a>

### Response assessment: T2-weighted signal intensity and tumor volume in the RINGSIDE phase 2 study

> “The Phase 2 part of the RINGSIDE study (NCT04871282) demonstrated early and continued MRI-based improvements in DTs with varegacestat (AL102) therapy”
> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”
> “On T2W images, hyperintense areas are associated with active fibroblast proliferation and hypointense areas are associated with loss of tumor cells and an increase in collagenous tissue”
> “These data add to a growing body of work showing T2W signal intensity and tumor volume may play a key role in evaluating treatment response in DT”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-2.2.1.5-12"></a>

### Response assessment: quantitative T2 mapping

> “However, the primary imaging endpoints based on RECIST1.1 used in these studies are determined only by changes in maximum tumor diameter.”
> “Analysis of T2 relaxation time maps of DF may offer a feasible quantitative biomarker for assessing the extent of response to treatment.”

Source: [Souza et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10766853/)

<a id="topic-2.2.1.5-13"></a>

### Misdiagnosis and time to diagnosis: participant-reported data

> “A total of 162 participants (41%, 162/399) reported a prior misdiagnosis.”
> “The median age at the first sign or symptom of DT was 32 years, and the average time from the first sign or symptom to confirmed DT diagnosis was 4 years ( n = 292; median = 1 year).”
> “The most reported differential diagnoses (70%, 113/162) were benign tumors or other conditions, including muscle injury, lipoma, colon polyps, postoperative scars, early-onset arthritis, hernia, and Baker’s cyst.”
> “Among 126 participants who reported a prior misdiagnosis and history of surgery for DT, 46% (58/126) reported having received surgery before a definitive DT diagnosis.”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.5-14"></a>

### Misdiagnosis before confirmed diagnosis: U.S. academic center

> “Therefore, we aimed to characterize the patient journey in DTs from diagnosis to treatment at an academic center in the United States.”
> “A total of 43 patients (29.1%) potentially had a misdiagnosis prior to a final confirmed diagnosis of DT based on tissue histology”
> “Most common misdiagnoses included other benign tumors ( n = 31, 20.3%), low-grade sarcomas ( n = 11, 7.2%), nodular fasciitis ( n = 4, 2.6%), and procedure-related scars ( n = 3, 2%).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.5-15"></a>

### Histologic misdiagnosis in published series

> “Based on pathologic similarities with other myofibroblastic diseases (e.g., sarcoma, gastrointestinal stromal tumor, nodular fasciitis, leiomyoma) and the low incidence of DT, 30–40% of DT cases are reported to be misdiagnosed following histologic analysis”
> “A French nationwide survey demonstrated that one-third of DT are misdiagnosed (the most challenging differential diagnoses are nodular fasciitis and low-grade fibromyxoid sarcoma)”

Source: [Bektas et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10427533/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
